PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer

Inclusion Criteria: * Resectable and operable esophageal cancer located under the carena (beyond 25 cm from the incisors) or junctional cancer (Siewert I or II) * Invasive adenocarcinoma or squamous cell type (to stick to the population included in the CROSS trial) * Patient who present with: * stage IIA (T3N0M0) * stage IIB (T1 N1 M0 or T2 N1 M0), * stage III (T3 N1 M0 or T4 N0 N1 M0) tumors * ECOG performance status 0, 1 or 2 * Patient eligible for preoperative chemoradiation with either fluorouracil- oxaliplatin-folinic acid, or Paclitaxel-carboplatin * Age ≥ 18 * Peripheral neuropathy ≤ NCI-CTC grade 1 * Adequate bone marrow reserve, normal renal and liver functions: * Neutrophil count ≥ 1500/mm3 * Platelet count ≥ 100 000/mm3 * Hemoglobin ≥ 10 g/dl (after transfusion, if necessary) * Creatinin \< 15mg/L * Clearance of creatinin (Cockcroft formulae) ≥ 60 ml/mn * Prothrombin time ≥ 60% * ASAT-ALAT ≤2.5 x ULN * Total bilirubin \< 1.5 x ULN * Albumin greater the lower limit of normal * Start of treatment within 28 days after randomization * Negative pregnancy test (serum beta-HCG) performed within 1 week prior to start of study treatment in females with reproductive potential * Patient covered by government health insurance * Patient who provide a signed written informed consent form Exclusion Criteria: * Patient who present with stage I or stage IIA (including T2 N0 M0) or stage IV * Patient who present with common contraindications for surgery …